Emerging medical treatments for hidradenitis suppurativa.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32289386.
- Also identified by DOI 10.1016/j.jaad.2020.04.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting intertriginous skin areas, and it is characterized by recurrent painful episodes of inflammatory drainage. Although the pathophysiology of HS is not fully understood, recent research points to an imbalance of cytokines as a contributing factor to the associated symptoms of purulent drainage and sinus tract formation. HS lesions are often characterized by a superimposed pathogenic/commensal bacterial infection that can improve with targeted antibiotic therapy. New medical treatments have emerged in recent years, many of which specifically work against a variety of proinflammatory mediators associated with HS. These newer, specified treatment options, in conjunction with surgery and lasers, are thought to provide positive outcomes and an overall improvement in quality of life in patients with HS.
Medical subject headings
- Dermatologic Agents
- Dermatologic Surgical Procedures
- Hidradenitis Suppurativa
- Laser Therapy
- Quality of Life